Conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 18-month efficacy and safety results from a large, randomized, open-label, comparative trial

被引：0
|
作者：
Pussell, B [1 ]
Russ, G [1 ]
Walker, R [1 ]
Campbell, S [1 ]
O'Connell, P [1 ]
Kanellis, J [1 ]
Eris, J [1 ]
机构：
[1] Prince Wales Hosp, Dept Nephrol, Randwick, NSW 2031, Australia
来源：
IMMUNOLOGY AND CELL BIOLOGY | 2006年 / 84卷 / 03期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：A19 / A20
页数：2
相关论文
共 50 条
  • [21] Effects of Conversion from Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplantation Recipients
    Li, L-C
    Hsu, C-N
    Lin, C-C
    Cheng, Y-F
    Chen, D-W
    Lee, C-H
    Chen, C-L
    TRANSPLANTATION, 2017, 101 (05) : 208 - 208
  • [22] Effects of Conversion From Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplant Recipients
    Tsai, Kai-Fan
    Li, Lung-Chih
    Hsu, Chien-Ning
    Lin, Chih-Che
    Lin, Yu-Hung
    Cheng, Yu-Fan
    Wang, Chih-Chi
    Chen, Chao-Long
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (03): : 326 - 334
  • [23] Conversion to sirolimus in kidney transplant patients receiving maintenance calcineurin inhibitor immunosuppression: A randomized, open-label, comparative clinical trial
    Schena, FP
    Wali, RK
    Pascoe, MD
    Alberu, J
    Rial, MD
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V165 - V166
  • [24] THE TRANSFORM TRIAL DESIGN: A LARGE RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY OF EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITORS IN DE NOVO RENAL TRANSPLANTATION
    Legendre, C.
    Srinivas, T-R.
    Pascual, J.
    Chadban, S.
    Citterio, F.
    Henry, M.
    Oppenheimer, F.
    Tedesco-Silva, H.
    Vincenti, F.
    Watarai, Y.
    Zeier, M.
    TRANSPLANT INTERNATIONAL, 2013, 26 : 23 - 24
  • [25] Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients
    Tedesco-Silva, Helio
    Peddi, V. Ram
    Sanchez-Fructuoso, Ana
    Marder, Brad A.
    Russ, Graeme R.
    Diekmann, Fritz
    Flynn, Alison
    Hahn, Carolyn M.
    Li, Huihua
    Tortorici, Michael A.
    Schulman, Seth L.
    TRANSPLANTATION DIRECT, 2016, 2 (04):
  • [26] Open-Label Study of Planned Transition from Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Demographics and Interim Safety Results.
    Tedesco-Silva, H.
    Peddi, R.
    Russ, G.
    Marder, B.
    Hahn, C.
    Li, H.
    Flynn, A.
    Schulman, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 337 - 337
  • [27] Renal Outcomes and Factors Predicting the Outcomes after Conversion to Sirolimus from Calcineurin Inhibitors in Chronic Renal Allograft Dysfunction.
    Swaminathan, Ramyasuda
    Irish, Ashley
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 585 - 585
  • [28] Chronic allograft damage index (CADI) scoring at conversion from calcineurin inhibitors (CI) to Sirolimus predicts renal outcome in kidney transplant recipients.
    Sankaranarayanan, N
    Balarezo, F
    Alleman, K
    Brown, M
    Charpentier, K
    Lally, A
    Hull, D
    Ranga, KV
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 296 - 296
  • [29] Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus
    Bumbea, V
    Kamar, N
    Ribes, D
    Esposito, L
    Modesto, A
    Guitard, J
    Nasou, G
    Durand, D
    Rostaing, L
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (11) : 2517 - 2523
  • [30] An openpilot study on the safety of a conversion from calcineurin inhibitors to sirolimus in patients with moderately impaired function of renal transplants.
    Fischereder, M
    Graeb, C
    Kammerl, MC
    Zuelke, C
    Jauch, KW
    Kramer, BK
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 770A - 770A
12345